Ocular Therapeutix, Inc.
OCULNASDAQHealthcare● Active
$8.28
+$0.03(+0.30%)
Market Cap$1.8B
P/E Ratio—
52W High$16.44
52W Low$6.23
Ocular Therapeutix, Inc. (OCUL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · OCUL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $51.82M | $63.72M | $58.44M | $51.49M | $43.52M |
| Cost of Revenue | $6.57M | $5.63M | $5.28M | $4.54M | $4.41M |
| Gross Profit | $45.25M | $58.10M | $53.16M | $46.95M | $39.12M |
| Gross Margin %(computed) | 87.31% | 91.17% | 90.96% | 91.18% | 89.88% |
| Operating Expenses | |||||
| R&D Expenses | $197.10M | $127.64M | $61.05M | $53.46M | $50.08M |
| G&A Expenses | $64.38M | $60.65M | $33.94M | $67.98M | $31.88M |
| Total Operating Expenses | $315.39M | $229.88M | $135.54M | $125.61M | $117.15M |
| Operating Income | ($270.02M) | ($171.78M) | ($82.38M) | ($78.65M) | ($78.04M) |
| Operating Margin %(computed) | -521.04% | -269.57% | -140.96% | -152.74% | -179.30% |
| Interest Income | $18.36M | $20.28M | $3.98M | $0.80M | $0.03M |
| Interest Expense | $11.84M | $13.58M | $11.34M | $7.02M | $6.67M |
| Income Before Tax | ($265.94M) | ($193.51M) | ($80.74M) | ($71.04M) | ($6.55M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($265.94M) | ($193.51M) | ($80.74M) | ($71.04M) | ($6.55M) |
| Net Margin %(computed) | -513.17% | -303.67% | -138.14% | -137.95% | -15.06% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.42 | $-1.22 | $-1.09 | $-1.04 | $-1.05 |
| Wtd Avg Shares | 187.24M | 158.26M | 79.83M | 76.88M | 76.39M |
| EBITDA | ($249.78M) | ($176.14M) | ($66.42M) | ($61.91M) | $2.54M |
| EBITDA Margin %(computed) | -481.99% | -276.42% | -113.64% | -120.22% | 5.83% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Ocular Therapeutix, Inc. data
About Ocular Therapeutix, Inc. (OCUL) Income Statement
Ocular Therapeutix, Inc. (OCUL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, OCUL reported revenue of $0.05B, gross profit of $0.05B (gross margin 87.31%), and net income of ($0.27B) — a net profit margin of -513.17%.
Frequently asked questions
OCUL · 4 questionsOcular Therapeutix, Inc. (OCUL) reported revenue of $0.05B for 2025, down 18.7% year-over-year.
OCUL revenueOCUL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08